SCHEMBL6482540

SCHEMBL6482540

O=S(=O)(Nc1cccc(CCOCc2ccc(-c3ccccn3)cc2)c1)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 2/20 0.42
CYSLTR1 Q9Y271 2/20 0.42
MAPT P10636 1/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
SIRT3 Q9NTG7 1/20 0.38
CA2 P00918 1/20 0.38
HSD11B1 P28845 1/20 0.37
FFAR1 O14842 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
KDM1A O60341 1/20 0.36
BRD4 O60885 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479679 0.84 KDM1A (0.42) CYSLTR2CYSLTR1MAPTPTGS1PTGS2
SCHEMBL6483863 0.83 PPARA (0.47) CYSLTR2CYSLTR1MAPTPTGS1PTGS2
SCHEMBL6482520 0.83 KIF11 (0.46) CYSLTR2CYSLTR1CA2KDM1A
SCHEMBL6475120 0.83 CYSLTR2 (0.47) CYSLTR2CYSLTR1MAPTPTGS1PTGS2
SCHEMBL6475717 0.82 CA2 (0.43) CYSLTR2CYSLTR1PTGS1PTGS2CA2
SCHEMBL6474092 0.82 PPARA (0.41) CYSLTR2CYSLTR1MAPTPTGS1PTGS2
SCHEMBL6474786 0.82 LTB4R (0.41) CYSLTR2CYSLTR1PTGS1PTGS2CA2
SCHEMBL6475739 0.81 PTPN1 (0.48) CYSLTR2CYSLTR1PTGS1PTGS2CA2
SCHEMBL6474738 0.81 CYSLTR2 (0.46) CYSLTR2CYSLTR1MAPTPTGS1PTGS2
SCHEMBL6482194 0.81 KDM1A (0.43) CYSLTR2CYSLTR1PTGS1PTGS2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 CYSLTR2 4703/4885CYSLTR1 4632/4885MAPT 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.